tetano
Editor, Senior Moderator
Yakugaku Zasshi. 2013;133(3):313-21.
Study of next generation influenza vaccine focused on "cross-protection by mucosal immunization" and "seed virus strains".
Okamoto S.
Source
National Institute of Biomedical Innovation, Laboratory of Virology and Vaccinology.
Abstract
Endemic infection by seasonal influenza virus usually occurs every winter season. Inside the host, human influenza viruses frequently undergo various point mutations at antigenic regions, in response to antibody pressure. Furthermore, the influenza virus has undergone frequent antigenic shifts for at least 100 years, some of which have caused influenza pandemics. In Japan, intramuscular immunization with influenza split-virion vaccines has been used to prevent seasonal influenza virus infections. Unfortunately, the efficacy of the current influenza vaccine immunization method is limited, even against viruses belonging to the same clade. Furthermore, the current vaccines are not expected to be protective against antigenically shifted viruses. Therefore, new approaches to vaccine development are needed to protect human populations against a potential pandemic virus. We are studying novel influenza vaccine designs to resolve the above weaknesses of the current influenza vaccines. I will describe our vaccine studies, "Cross-protection by mucosal immunization," and, "Preparation of seed virus strains to produce vaccines for possible pandemic influenza," in this symposium.
PMID:
23449407
[PubMed - in process]
Free full text
http://www.ncbi.nlm.nih.gov/pubmed/23449407
Study of next generation influenza vaccine focused on "cross-protection by mucosal immunization" and "seed virus strains".
Okamoto S.
Source
National Institute of Biomedical Innovation, Laboratory of Virology and Vaccinology.
Abstract
Endemic infection by seasonal influenza virus usually occurs every winter season. Inside the host, human influenza viruses frequently undergo various point mutations at antigenic regions, in response to antibody pressure. Furthermore, the influenza virus has undergone frequent antigenic shifts for at least 100 years, some of which have caused influenza pandemics. In Japan, intramuscular immunization with influenza split-virion vaccines has been used to prevent seasonal influenza virus infections. Unfortunately, the efficacy of the current influenza vaccine immunization method is limited, even against viruses belonging to the same clade. Furthermore, the current vaccines are not expected to be protective against antigenically shifted viruses. Therefore, new approaches to vaccine development are needed to protect human populations against a potential pandemic virus. We are studying novel influenza vaccine designs to resolve the above weaknesses of the current influenza vaccines. I will describe our vaccine studies, "Cross-protection by mucosal immunization," and, "Preparation of seed virus strains to produce vaccines for possible pandemic influenza," in this symposium.
PMID:
23449407
[PubMed - in process]
Free full text
http://www.ncbi.nlm.nih.gov/pubmed/23449407